Antibody‐based cancer therapy, one of the most significant therapeutic strategies, has
achieved considerable success and progress over the past decades. Nevertheless …

Active targeting in cancer nanomedicine, for improved delivery of agents and diagnose, has
been reviewed as a successful way for facilitating active uptake of theranostic agents by the …

In the last decade, cancer immunotherapies have produced impressive therapeutic results.
However, the potency of immunotherapy is tightly linked to immune cell infiltration within the …

In recent years, nanoparticulate-mediated drug delivery research has examined a full
spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer …

Nanobodies are the smallest fragments of naturally occurring heavy-chain antibodies that
have evolved to be fully functional in the absence of a light chain. As such, the cloning and …

The development of monoclonal antibody treatments for successful tumor-targeted therapies
took several decades. However, the efficacy of antibody-based therapy is still confined and …

Targeted therapy is a fast evolving treatment strategy to reduce unwanted damage to
healthy tissues, while increasing efficacy and specificity. Driven by state-of-the-art …

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid
alternative to conventional monoclonal antibodies also for clinical applications. Furthermore …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

Although recent successes in clinical trials are strengthening research focused on cancer
immunology, the poor immunogenicity and off-target side effects of immunotherapeutics …